Pictured: Ned Jessen (far left) with his family, including grandson Edgar (center), and daughter Margaret (third from left)

When a grandfather meets his grandchild for the first time, a powerful bond is created. It’s a bond that creates an unspoken promise of love that is both vulnerable and fierce, one that that celebrates every milestone and catches every fall.

Ned Jessen is a grandfather who gets to experience this special bond with his grandson, Edgar, in a unique way. In November of 2021, Edgar was diagnosed with type 1 diabetes (T1D) at the age of 11.

“When Edgar was diagnosed, I watched how overwhelming and frightening it was for his parents—my daughter and her husband—and him,” says Ned. “Edgar’s diagnosis was life-changing, yet he and his parents have handled it so gracefully.”

Breakthrough T1D’s prominent presence

Ned’s daughter, Margaret Jessen Kelley, says that while Edgar’s life will never be the same, they have hope…because they have Breakthrough T1D. “Breakthrough T1D was everywhere during Edgar’s diagnosis and continues to show up through community and progress that impacts Edgar’s quality of life,” says Margaret.

It’s that prominent presence and impact that inspired Ned to join the Breakthrough T1D community in achieving a world without T1D by including a legacy gift in his estate plans.

“Breakthrough T1D has been there every step of the way for my daughter, Edgar, and our family. We’ve met some of the most kind and gracious people, as well as incredibly smart and talented people. We know Breakthrough T1D is going to do the work needed for Edgar to succeed,” says Ned. “This is why our family has decided to support Breakthrough T1D through both a legacy gift and a current pledge.”

Ned’s hope and confidence in Breakthrough T1D shine brightly in the legacy he has created to honor for his grandson, Edgar. It’s a legacy that promises to create a better life for his grandson and others with type 1 diabetes, and a legacy that is imperative to changing T1D’s history in this world.

To learn more about how legacy gifts will achieve Breakthrough T1D’s vision of a world without T1D, visit BreakthroughT1D.plannedgiving.org.

Halloween is one of the most anticipated holidays of the year for kids and adults alike. Dressing up in costume, going trick-or-treating, and devouring candy is a tradition for many families. 

But the fear of hard-to-manage blood sugar can make Halloween more stressful than exciting for those living with type 1 diabetes (T1D).

Don’t be scared, be prepared! Breakthrough T1D has you covered with our easy-to-use Halloween Guide, with tips and suggestions to help you have a fun and safe holiday. And our list of carb counts for popular Halloween candies is a great resource to print out and hang on the fridge for quick reference.

For adults with T1D who celebrate Halloween, if you’re going to be enjoying alcoholic beverages, be sure to visit our guide to drinking safely with T1D.

We hope you stay healthy, have fun, and enjoy the spooky season!

Leading researchers gathered in Stockholm and virtually for the annual meeting of the European Association for the Study of Diabetes (EASD), which took place from September 19-23. There were more than 20,000 attendees and featured more than 30 studies presented by Breakthrough T1D-funded researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the disease today.

Here are a few highlights:

DKA is a life-threatening complication that normally happens when blood sugar is very high. But with SGLT therapy, DKA can present with blood-sugar levels at normal or near it. Because of this, people with T1D on an SGLT therapy need to do ketone testing (ketoacidosis is an abundance of ketones in the blood), to avoid DKA and potential hospitalization.

Breakthrough T1D funding helped create the algorithm and pump for this partnership. The algorithm was developed by Roman Hovorka, Ph.D., who had several Breakthrough T1D grants from 2006 to 2019, coming to the UK market in 2020. Ypsomed has an active grant from Breakthrough T1D, from 2018-2023, to develop a mylife™ insulin pump for artificial pancreas systems.

The next two conferences we’ll be covering are the Advanced Technologies & Treatments for Diabetes (ATTD), from February 22-25 in Berlin, and the Breakthrough T1D-sponsored Network for Pancreatic Organ Donors with Diabetes (nPOD) Scientific Meeting, from February 26-March 1 in Fernandina Beach, Florida. Stay tuned for a precap and recap of these outstanding meetings!

Leading researchers from around the world have gathered for the annual meeting of the European Association for the Study of Diabetes (EASD). At this year’s meeting, which took place from September 20-23 in Stockholm, Sweden, and virtually, more than 30 studies will be presented by Breakthrough T1D researchers, funded now or in the past, working to find cures for type 1 diabetes (T1D) and improve the lives of those living with the disease today. Let’s have a look:

Since 2007, when the Albert Renold Prize was given out annually, a total of 13 investigators have received Breakthrough T1D funding prior to winning the prize, including 5 Breakthrough T1D early-career scientist grants. (Dr. Sander was a Breakthrough T1D postdoctoral fellow from 1997-1999 and has received many more awards since.)

Smart insulin pens and pen caps offer people with type 1 diabetes (T1D) a different way to use technology to manage and deliver insulin.  

Some people with T1D find smart insulin pens are a good alternative to their insulin pumps and automated insulin delivery systems (also called artificial pancreas systems or AP systems) when they want to take a break from being “attached” all the time.  

Taking a “pump pause” has more implications today than it has in the past. This is especially the case if you are using an automated insulin delivery system/AP system to manage your type 1 diabetes. 

Ryan ThompsonThe first FDA-approved smart insulin pen, Medtronic’s InPen, was launched in 2016. Since then, several other connected insulin pens and caps have arrived on the market, including Bigfoot’s Unity smart cap and Novo Nordisk’s NovoPen 6 and NovoPen Echo Plus.

Ryan Thompson started using a smart insulin pen in March 2022, after being on an insulin pump for 15 years. His active lifestyle and desire to try something new informed his decision.

“It blended a mix of new technology with the app and a familiar experience with the pen format,” Ryan said. “Each person with diabetes needs to do what is best for their lifestyle.”

Tubeless technology

Connected pens and pen caps use Bluetooth technology to send dose information to a mobile app, which helps users track insulin dosage. Smart insulin pens calculate doses and identify trends. This technology relieves some of the mental math burden of T1D, similar to an insulin pump. The InPen and Unity smart cap also work with select CGMs to make dosing with them even easier! 

5 reasons to consider a pump pause

So, why do some people with type 1 diabetes use summer as an opportunity to take a pump pause? Here’s a list of 5 reasons that might inform your decision:  

  1. Sweat and sunscreen can make pump site adhesives a challenge to keep on. With a smart pen or pen cap, you don’t need to worry about extra tape or overlays. “I have always loved the beach,” Ryan said. “The freedom of not having tubing or a wet pump site is great.”
  2. Some smart pens, including Medtronic’s InPen, have temperature alerts that notify you if the insulin gets too hot (or too cold), a convenient reminder when you’re spending time in the summer sun. Some insulin pumps also have this feature.
  3. Packing for a summer vacation with T1D can add another suitcase of supplies. Smart insulin pens are refillable, so all you need is the insulin cartridge to deliver boluses. (But don’t forget to pack the rest of your supplies, like blood glucose meters, CGMs and glucagon!) “I travel a lot for leisure,” Ryan said. “The InPen tucks away in my carry bag very easily and does not require additional TSA security measures, which is welcomed!”
  4. We’re big fans of showing off your T1D technology and of the improved health outcomes pumps and AP systems help people achieve, but some people may view pump-wearing as something they’d rather not deal with when wearing bathing suits, shorts, and sundresses. A smart pen means you don’t need to be MacGyver when getting dressed in the hotter months.
  5. With a smart insulin pen, you can use injection sites that may not always be practical for a pump site (looking at you, beltline), which could result in improved absorption—not a bad thing for carb-heavy summer BBQs. 

Use the tools that work best for you

“One of Breakthrough T1D’s goals is to make sure that everyone has the diabetes management tools that work best for them,” said Associate Director of Research at Breakthrough T1D, Jonathan Rosen, Ph.D. “While we have driven forward the development of AP systems, which consist of a pump, CGM, and controller, and have demonstrated benefits in improving outcomes and reducing disease burden, we appreciate that not everyone wants to wear a pump and are thrilled to see the progress in smart pens. Smart pens can aid with many aspects of T1D care, including helping users determine when to take insulin and what the dose should be, which helps relieve the daily burden of T1D.”  

If you are considering any changes to your diabetes management plan, discuss it first with your healthcare provider. 

Any way you choose to manage your T1D this summer, stay safe and have fun!  

Editor’s Note: This educational content is made possible with support from Medtronic.  Breakthrough T1D produces this content to provide information to our supporters about their potential options for managing their T1D and not as an endorsement of products. Editorial control rests solely with Breakthrough T1D. 

The Association of Diabetes Care & Education Specialists (ADCES) goal is to improve diabetes outcomes through innovative education, management, and support, and it has over 12,000 members. Each year, they give out a number of awards. These are a big deal. And, this year, the 2023 Diabetes Care and Education Specialist of the Year Award is going to <drumroll please> Anastasia Albanese-O’Neill, Ph.D., APRN, CDCES, Breakthrough T1D’s director of community screening and clinical trials education!

The award recognizes a diabetes specialist who has made a special contribution through dedication and innovation in the daily practice of patient care. And, oh, has Anastasia made a profound contribution! Let’s take a look:

And I could go on and on…but I won’t. (But she’s got a resumé that would make anyone’s head swirl!)

The award was given to her at the ADCES Annual Conference on August 12-15, 2022. The award also provides a cash prize and a commemorative plaque.

Please applaud Anastasia on her congratulatory and well-deserved honor!

Jennifer Bennett, managing director and associate general counsel in the Office of the Corporate Secretary for Bank of America Corporation in Charlotte, North Carolina, has been appointed Chair of the Breakthrough T1D Global Mission Board (GMB), effective July 1, 2022.

The Breakthrough T1D GMB also welcomes new members Meredith Coors (Mountain West Chapter), Laura Cramer (Mid-Atlantic Chapter), Maarten de Groot (Breakthrough T1D Netherlands), Gwen Malone (Pacific Northwest Chapter) and David Schwab (Mid-Atlantic Chapter), to help drive mission progress through volunteer engagement.

The Breakthrough T1D GMB, created in 2019, is a group of volunteer leaders who collaborate with staff leaders to advance Breakthrough T1D’s mission through special initiatives in research, advocacy, fundraising, and community engagement. Jennifer will be the second-ever Chair of the GMB, following Kim Roosevelt, who served in the role for the last three years.

Vanguard Volunteer

Jennifer became part of Breakthrough T1D 17 years ago when her child, Rain, was diagnosed with type 1 diabetes (T1D) at the age of three. Her family has participated in the Breakthrough T1D One Walk every year since Rain’s diagnosis.

Jennifer’s dedication to Breakthrough T1D is unmistakable. Jennifer has volunteered in many roles in Breakthrough T1D’s North Carolina Chapter, including as Chapter Board President and Executive Council Chair. At the national level, she previously served on the International Board of Directors (IBOD) and is currently on the IBOD’s Nominating and Governance Committee and the Talent and Compensation Committee. She has been a member of the GMB’s leadership since 2019, heading the fundraising and engagement pillar.

“Our Global Mission Board plays a critical role in Breakthrough T1D’s Mission and in recruiting and engaging volunteers,” said Aaron J. Kowalski, Ph.D., Breakthrough T1D Chief Executive Officer. “I’m confident that our GMB, together with Jennifer and its newest board members, will harness the passion of our volunteers to accelerate our mission progress and move us even closer to a world without type 1 diabetes.”

Steve Davis was a leader in the restaurant and consumer packaged goods industries, but to Breakthrough T1D, he was a beloved member of the Breakthrough T1D family and our International Board of Directors. It is with incredible sadness and heavy hearts that we share that Steve passed away of sudden cardiac arrest on July 10, 2022.

We are forever grateful for Steve’s many years of service to Breakthrough T1D, as well as the time, talent, and support he generously dedicated to changing the world for people living with type 1 diabetes.  Steve and his wife, Lynnda, got involved with Breakthrough T1D’s Central Ohio chapter when their daughter was diagnosed with T1D in 2009. Since then, they worked tirelessly to accelerate Breakthrough T1D’s mission, fund critical research, and drive life-changing breakthroughs to cure, prevent, and treat T1D.

Steve served as CEO of Bob Evans from 2006 – 2015 and during that time, he and Lynnda were instrumental in promoting and partnering with Breakthrough T1D through store campaigns, community fundraisers, and Walk Sponsorships. In addition, Steve’s legacy of impactful contributions includes:

Steve served on Breakthrough T1D’s International Board of Directors since 2017, was a member of the Funding Committee, and most recently served as the Nominating and Governance Committee Chair for the last three years.

Steve was a true T1D champion and changemaker. The impact of his philanthropic efforts will benefit the T1D community for years to come and we are grateful for the role he played in bringing us closer to curing T1D than we’ve ever been.

Please keep Lynnda, their three daughters Brittany, Stephanie and Cassie, and the entire Davis family in your thoughts and prayers during this incredibly difficult time.

At the American Diabetes Association’s 82nd Scientific Sessions, which was held in person (as well as virtually) from June 3-7, scientists presented on some of the most important topics, from stem cell-derived cell replacement trials to type 1 diabetes (T1D) screening to artificial pancreas technologies, all with the same goal: Ending T1D.

Breakthrough T1D played the roles of presenter, educator, and active learner—and was the key funder and supporter of nearly all the top advances shared in T1D research. There were many fantastic results that came through the ADA’s Scientific Sessions. Here is Aaron J. Kowalski, Ph.D., CEO of Breakthrough T1D, with the key takeaways from the conference, and there is a written summary of Breakthrough T1D highlights below.

You can view all of the oral and poster presentations on the Diabetes journal website.

Cures

Stem Cell-Derived Beta Cell Therapy: Advancing Clinical Trials

Breakthrough T1D Research Area: Cell Therapies

Cell replacement therapies, including stem cell-derived islet therapy, were on fire, with Vertex Pharmaceuticals and ViaCyte leading the way in clinical trials. Vertex launched its clinical trial of VX-880, a stem cell-derived beta cell therapy in T1D, in combination with immunosuppressive therapy to protect the cells from rejection, in the summer of 2021. To date, three participants have received the drug, and one is now insulin independent! ViaCyte, in partnership with CRISPR Therapeutics, initiated its first-in-human gene-edited, stem cell replacement therapy, without immunosuppression, called VCTX210.

Breakthrough T1D Leadership

Vertex’s VX-880 therapy was pioneered by Doug Melton, Ph.D.—who moved from Harvard to Vertex Pharmaceuticals to work on their stem cell-derived cell replacement therapies—after successfully transforming stem cells into beta cells in 2014. Another pioneer in cell replacement therapies for T1D is Timothy Kieffer, Ph.D., who also recently moved from the University of British Columbia to serve as Chief Scientific Officer at ViaCyte. They had Breakthrough T1D funding from 2000 on.

We also heard from Sernova, who provided an update on the phase I/II clinical trial of their Cell Pouch™—an implantable device designed to form a natural environment and allow the survival and function of insulin-producing (islet) cells. The first three individuals to receive the therapy into the Cell Pouch™, with a supplemental marginal dose of islet cells via the portal vein, have been insulin independent for 2 years, 6 months, and 3 months, respectively. Breakthrough T1D continues to support Sernova to make their Cell Pouch part of the cure portfolio.

Meeting attendees also heard clinical and preclinical data updates from several investigations on encapsulation and immune-tolerance strategies to protect transplanted islet cells from the immune system, featuring a world-renowned set of T1D researchers, including Breakthrough T1D-funded James Shapiro, M.D., Ph.D. (who is known for his leadership on the Edmonton Protocol), and Andrew R. Pepper, Ph.D., of the University of Alberta, Canada, Bernhard Hering, M.D., from the University of Minnesota, and José Oberholzer, M.D., of the University of Virginia.

Immune Mechanisms of T1D: Innate Versus Adaptive Immunity…or Both

Breakthrough T1D Research Area: Disease-Modifying Therapies

Adaptive immune cells are responsible for T1D, but beta cell stress and dysfunction precede this onslaught, with innate immune cells taking charge. It turns out that the prohormone to islet amyloid polypeptide (proIAPP, for short)—as C. Bruce Verchere, Ph.D., and Rebecca Hull-Meichle, Ph.D., discussed in their presentations—is elevated prior to clinical diagnosis, in addition to proinsulin—the precursor to insulin. proIAPP, in turn, sparks inflammation and innate immune cell damage. Dr. Verchere has developed a test to measure two kinds of proIAPP in humans, which, ultimately, will provide new insight into the immune cell types and immune mechanisms leading to beta cell function and pave the way for new therapies and biomarkers of beta cell stress.

Breakthrough T1D Leadership

Dr. Verchere received a Breakthrough T1D postdoctoral fellowship beginning in 1992 and Dr. Hull-Meichle received one in 2001-2003. The titles, respectively: “Role of Islet Amyloid Polypeptide in Normal and Abnormal Islet Function” and “The Role of Islet Amyloid Formation in Diabetes.” More recently, Heather Denroche, Ph.D., who Dr. Verchere credits in his presentation, received a Breakthrough T1D postdoctoral fellowship from 2014-2017 and an advanced postdoctoral fellowship from 2018-2022.

“Breakthrough T1D’s support has been instrumental to my development as a scientist and allowed me to make valuable contributions to type 1 diabetes research….I am truly grateful for this experience.”

– Heather Denroche, Ph.D.
Director, Preclinical Development
Integrated Nanotherapeutics

Dr. Verchere is now leading the Breakthrough T1D Center of Excellence at the University of British Columbia, where he is working on immune and beta cell therapies, including stem cell-derived therapies, with Dr. Kieffer; James Johnson, Ph.D., who received a Breakthrough T1D Career Development Award in 2005-2010; Francis Lynn, Ph.D., who was a Breakthrough T1D postdoc from 2004-2006, advanced postdoc from 2007-2009, and a Breakthrough T1D Alan Permutt Career Investigator from 2012-2016; and Megan Levings, Ph.D., who has received two Breakthrough T1D grants since 2015 and has been a mentor to two Breakthrough T1D postdocs.

General Population Screening: It’s Time

Breakthrough T1D Research Area: Screening

Several Breakthrough T1D-funded researchers presented on the current state of screening for genetic risk and/or T1D-related autoantibodies—antibodies that are directed toward your own body. Chantal Mathieu, M.D., Ph.D., gave a spirited talk about why it’s time to screen for T1D in the general population. The first point: T1D is a serious and important health problem and we have learned a lot from family screening and prevention studies. The second point: Decreasing diabetic ketoacidosis (DKA)—a complication of T1D due to a shortage of insulin levels in the body—should be, in itself, enough to warrant population screening. Post-screening, we must be ready with follow-up and guidance so families know what to do with autoantibody status, including clinical trials, like teplizumab—and screening will help identify populations who can benefit from them.

“100 years after the development of insulin, we still have people dying from DKA in all of our countries.”

– Chantal Mathieu, M.D., Ph.D.
KU Leuven, Belgium
Coordinator, INNODIA

Breakthrough T1D Leadership

As a result of decades of Breakthrough T1D-funded research, we can identify those at highest risk for developing T1D—two or more autoantibodies—and we have funded screening programs since they were first introduced in the late 1980s. More recently, Breakthrough T1D has a new initiative, T1Detect, to broaden screening to the general population. The goal: Global universal screening, which is key to developing disease-modifying therapies to keep the disease from progressing and, ultimately, prevent it entirely.

Improving Lives

From the DIY System and Klue to the Omnipod 5 and the iLet Bionic Pancreas

Breakthrough T1D Research Area: Artificial Pancreas

A ton of presentations focused on the artificial pancreas, or automated insulin delivery (AID), systems. The first: Results from the first randomized clinical trial testing a do-it-yourself, or DIY, open-source, community-built AID technology, using the OpenAPS algorithm plus the DANA or YpsoPump insulin pump and the Dexcom G6 continuous glucose monitor (CGM). The study included 100 children and adults in New Zealand who used the DIY system compared to those without the algorithm, headed by Breakthrough T1D grantees Martin de Bock, Ph.D. (who also gave the presentation), and Dana Lewis, the founder of the DIY artificial pancreas system movement. There was no severe hypoglycemia and no DKA and more participants achieved time-in-range of ˃70% using the OpenAPS algorithm, especially at night: Conclusion: The open-source AID was safe and effective in T1D compared to those without the algorithm.

Next up: Researchers presented results from a novel closed loop system that eliminates manual mealtime bolusing. Medtronic teamed up with Klue, an Apple-watch based application that detects eating hand gestures, to see if it could provide a “handsfree” artificial pancreas system. The system converted hand gestures to carb amounts and automatically bolused via a Medtronic 780G pump, and there was no significant difference in time-in-range achieved with this system compared to when participants bolused manually. By eliminating the burden of carb-counting, this system may improve the quality of life in persons with T1D without sacrificing glycemic outcomes.

Next: Omnipod 5, a tubeless hybrid closed loop system, in preschool children. Presenting on this was Daniel DeSalvo, M.D., who had a Breakthrough T1D postdoctoral fellowship from 2014-2016, with world-renowned researcher Bruce Buckingham, M.D. This was an extension study, to evaluate if glycemic outcomes continued at 12 months (compared to the 3 months in the pivotal trial), and they did! At 12 months, these children had lower A1c and greater time-in-range, and there was no DKA or severe hypoglycemia, indicating the potential long-term benefit of the Omnipod 5 in very young children with T1D. The Omnipod 5 is under FDA review for ages 2-5 years; let’s hope this study will resolve any fears that the AID system is not warranted in preschool aged children.

And finally, the results from the randomized insulin-only iLet bionic pancreas pivotal trial. These were presented by Steven Russell, M.D., Ph.D., at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in April 2022, but now we have patient reported outcomes, presented by Jill Weissberg-Benchell, Ph.D., a professor at the Ann & Robert H. Lurie Children’s Hospital of Chicago, who discussed adults, with many reporting decreased distress, with less worry, guilt, and burnout due to increased time-in-range and no need to carbohydrate count, and youth, who reported positive experiences, including improved A1c, increased independence, and less time managing diabetes.

Breakthrough T1D Leadership

Dr. Russell received a Breakthrough T1D grant from 2013-2016 to refine the iLet pancreas, based upon the work of Ed Damiano, Ph.D., CEO of Beta Bionics, who Breakthrough T1D funded from 2009-2011, for his early research testing the safety and efficacy of a novel closed-loop system (including Firas El-Khatib, Ph.D., a Breakthrough T1D postdoctoral fellow in his lab). The results of this work helped to inform the development of the iLet bionic pancreas.

Diabetic Retinal Disease—Changing Before Your Eyes

Breakthrough T1D Research Area: Complications

Sobha Sivaprasad, M.D., reported on The Restoring Vision Moonshot, a “really radical” approach to end diabetic eye disease. The Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, which is used to assess progression of retinopathy, was developed in the 1950s and was limited to point-in-time visual perception, but Dr. Sivaprasad is part of 50 global experts, who will review the literature on diabetic eye disease “in the next year,” and come up with an evidence-based updated retinopathy staging scale, creating recommendations incorporating decades of progress in functional imaging, other biomarkers, and metrics of quality of life. When it’s completed, the improved staging scale will lead to the development of early preventive therapies that will reduce vison-threatening retinopathy progression, and ultimately improving the quality of life for people with T1D.

Breakthrough T1D Leadership

Breakthrough T1D has supported eye disease research since its beginning, and has driven discoveries that have reduced the risk of blindness by 95 percent, including laser therapy and anti-VEGF treatments. In 2018, Breakthrough T1D and the Mary Tyler Moore and S. Robert Levine, MD, Foundation launched the Restoring Vision Moonshot, an ambitious initiative to reverse diabetes-related blindness and vision-threatening eye disease, which afflicts millions of individuals worldwide, held in honor of Mary Tyler Moore’s contributions to diabetes awareness and research.

Improving Health Equity in T1D

Breakthrough T1D Research Area: Psychosocial

Many Breakthrough T1D-funded researchers presented on psychosocial issues, including the stigma associated with diabetes, suicide and self-harm, and social inequities—economically vulnerable, minorities, food insecurity—in diabetes care. Specifically, Shivani Agarwal, M.D., M.P.H., and Jeffrey Gonzalez, Ph.D., who have a new grant from Breakthrough T1D to evaluate telehealth in minority children and teens, and David V. Wagner, Ph.D., who had a Breakthrough T1D advanced postdoctoral fellowship from 2000-2003 and a number of Breakthrough T1D grants since, spoke to the many populations who experience poor outcomes in T1D and how they can be addressed. There is a lot of work to be done to improve outcomes for all people with T1D, both in the United States and around the world, but Breakthrough T1D is committed to helping reduce the significant daily burden of this disease and, ultimately, improve health outcomes for the entire T1D community.

You can view all of the oral and poster presentations on the Diabetes journal website.

The American Diabetes Association’s (ADA) 82nd Scientific Sessions is almost here! From June 3-7, scientists and healthcare professionals will gather—in person!—at one of the largest conferences of diabetes researchers in the world. Breakthrough T1D researchers and Breakthrough T1D-funded scientists will also be there virtually to hear first-hand and present new study results that will improve outcomes for people with type 1 diabetes (T1D). Read what’s happening below.

ADA’s 82nd Scientific Sessions

Curing T1D

Improving Lives

Throughout the Scientific Sessions, Breakthrough T1D will be sharing updates to keep people apprised of the day-to-day happenings: